

Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies *LRRC4C*, *LHX5-ASI* and nominates ancestry-specific loci *PTPRK*, *GRB14*, and *KIAA0825* as novel risk loci for Alzheimer’s disease: the Alzheimer’s Disease Genetics Consortium

[Authorship and Affiliations on pages 40-46]

(Short Running Title: ADGC Multi-Ancestry GWAS)

Address correspondence to:

Adam Naj, PhD
University of Pennsylvania Perelman School of Medicine
921 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
Phone: (215) 746-4180
Fax: (215) 573-1050

Word Count: 4,626
Abstract: 212
Text: 4,414

Keywords: Genome-wide association study (GWAS), GWAS Meta-Analysis, Alzheimer Disease, multi-ancestry, ancestry-specific

Draft #9

Date June 28, 2023

ABSTRACT

Limited ancestral diversity has impaired our ability to detect risk variants more prevalent in non-European ancestry groups in genome-wide association studies (GWAS). We constructed and analyzed a multi-ancestry GWAS dataset in the Alzheimer's Disease (AD) Genetics Consortium (ADGC) to test for novel shared and ancestry-specific AD susceptibility loci and evaluate underlying genetic architecture in 37,382 non-Hispanic White (NHW), 6,728 African American, 8,899 Hispanic (HIS), and 3,232 East Asian individuals, performing within-ancestry fixed-effects meta-analysis followed by a cross-ancestry random-effects meta-analysis. We identified 13 loci with cross-ancestry associations including known loci at/near *CR1*, *BIN1*, *TREM2*, *CD2AP*, *PTK2B*, *CLU*, *SHARPIN*, *MS4A6A*, *PICALM*, *ABCA7*, *APOE* and two novel loci not previously reported at 11p12 (*LRRC4C*) and 12q24.13 (*LHX5-ASI*). Reflecting the power of diverse ancestry in GWAS, we observed the *SHARPIN* locus using 7.1% the sample size of the original discovering single-ancestry GWAS ($n=788,989$). We additionally identified three GWS ancestry-specific loci at/near (*PTPRK* ($P=2.4\times 10^{-8}$) and *GRB14* ($P=1.7\times 10^{-8}$) in HIS), and *KIAA0825* ($P=2.9\times 10^{-8}$ in NHW). Pathway analysis implicated multiple amyloid regulation pathways (strongest with $P_{\text{adjusted}}=1.6\times 10^{-4}$) and the classical complement pathway ($P_{\text{adjusted}}=1.3\times 10^{-3}$). Genes at/near our novel loci have known roles in neuronal development (*LRRC4C*, *LHX5-ASI*, and *PTPRK*) and insulin receptor activity regulation (*GRB14*). These findings provide compelling support for using traditionally-underrepresented populations for gene discovery, even with smaller sample sizes.

INTRODUCTION

Alzheimer's disease (AD) affects over a third of people aged 80 years or older¹, with AD prevalence continuing to increase with the growth in the global population of elderly. Currently, there are approximately 50 million persons with AD worldwide, projected to increase to 135-200 million by 2050¹. Coupled with the facts that there are limited therapeutic interventions for AD and that this disease affects individuals of all ancestries, the expanding burden of AD makes this disease an urgent global public health crisis. Genome-wide association studies (GWAS) have identified over 75 risk loci associated with risk of AD and related dementias²⁻⁵, providing critical insights into molecular mechanisms underlying disease development. These studies, however, have been conducted predominantly in populations of European ancestry, although it is clear that ethnobiological origin (i.e. genetic ancestry) impacts genotypic risk, with rare variants in particular usually being shared only between genetically closely-related populations. This has limited the ability to identify ancestry-specific variants and loci⁶⁻⁸, determine shared genetic risk and protective factors across ancestrally-diverse populations⁹, and to capitalize on differential linkage disequilibrium (LD) structures across varied ancestral genetic backgrounds to improve fine-mapping of causal loci¹⁰⁻¹³. Thus, progress towards genetic prediction and precision medicine is significantly hampered by lack of data from non-European populations¹⁴.

Though concepts of race, ethnicity, and ancestry are often conflated¹⁵, our study focuses on genetic ancestry as shared genetic background through biological descent from common ancestors, where common ancestors may be defined over varying windows of generational time. For the purposes of this analysis, this may include individuals of more genetically homogeneous groups such as European (non-Hispanic whites (NHW)) and East Asian (EAS) ancestry groups, as well as groups with more recent admixture of previously ancestrally-divergent groups, such as

African Americans (AFA), whose genetic ancestries includes admixture from African and European ancestries, and Hispanics (HIS), whose genetic ancestries include highly variable levels of admixture predominantly between Amerindian, European, and African ancestries and with distinctly different admixture patterns geographically.

To identify novel loci associated across ancestrally-diverse populations and explore differences in genetic association across these groups, the ADGC initiated the first large-scale multi-ancestry GWAS meta-analysis with direct genotyping and either clinical evaluation of, or pathological confirmation of, AD status on over 56,000 individuals of diverse ancestral backgrounds, including 6,728 AFA, 8,899 HIS, 3,232 EAS, and 37,382 NHW participants. We analyzed imputed genotypes derived from the multi-ancestry Trans-Omics for Precision Medicine (TOPMed) R5 haplotype reference panel (308,107,085 variants from 97,256 sequenced individuals). We conducted a two-stage, cross-ancestry GWAS meta-analysis of AD followed by secondary analyses including ancestry-aware fine-mapping to understand genetic architecture underlying novel genetic loci and to identify shared and distinct differences of AD risk and protective loci in ancestrally-diverse populations.

RESULTS

The ADGC assembled the largest multi-ancestry collection of AD samples to date, containing 24,388 participants with AD and 31,853 cognitively unimpaired individuals passing quality control (QC) from 41 NHW, 12 AFA, eight HIS, and five EAS datasets (**Supplementary Table 1**). Notably, in contrast to several previously reported studies^{4,5}, all samples utilized in these analyses were directly genotyped and either clinically assessed or pathologically evaluated, which significantly increased the precision of the analyses. Descriptions of recruitment and

diagnosis of AD for newly added and previously available datasets are reported in the **Supplementary Note**, and sample sizes and genome-wide single nucleotide polymorphism (SNP) array platforms for the 66 individual datasets are reported in **Supplementary Table 2**. We excluded individuals younger than age 65 years at the time of censoring (age-at-onset [AAO] of symptoms for AD cases or age-at-last-examination/ age-at-death [AAE] for cognitively-normal elders [CNEs]). Intact cognition among living CNEs was confirmed with cognitive evaluations and absence of AD pathology among deceased CNEs.

Cross-Ancestry Genome-wide Association Meta-analysis

We first conducted a genome-wide association study (GWAS) for AD separately in each dataset using the two covariate adjustment models (without and with adjustment for *APOE* ϵ 4 dosage). Subsequently, within each model, we performed a fixed-effects meta-analysis to combine results across datasets within each ancestry (NHW, HIS, AFA, and EAS) (**Supplementary Tables 3-6, Supplementary Figures 1a-d and 2a-d**). Q-Q plots for ancestry-specific GWAS results (**Supplementary Figures 3a-d and 4a-d**) for both models in HIS, AFA, and EAS showed no genomic inflation ($\lambda=0.96-1.00$), while those in NHW in the *APOE* ϵ 4-unadjusted model showed moderate genomic inflation ($\lambda=1.09$; after *APOE* ϵ 4 adjustment, $\lambda=1.06$) (**Supplementary Figure 3a**). After cross-ancestry meta-analysis without (**Figure 1**) and with *APOE* ϵ 4 adjustment (**Supplementary Figure 5, Supplementary Table 7**) allowing for between-ancestry heterogeneity, we observed modest genomic deflation for either model ($\lambda=0.94-0.95$) (**Supplementary Figure 6**).

APOE ϵ 4-Unadjusted Model

In cross-ancestry meta-analysis under the *APOE* ϵ 4-unadjusted model, two novel genome-wide significant (GWS; $P \leq 5 \times 10^{-8}$) variants were detected near the genes *LRRC4C* on

chromosome 11 (rs12576934: odds ratio [OR]=1.12, 95% confidence interval [95% CI]=1.08-1.16, $P=5.4\times 10^{-9}$) and *LHX5-AS1* on chromosome 12 (rs111486601; OR=0.63, 95% CI=0.32-1.23, $P=1.1\times 10^{-8}$) (**Figures 1-2** and **Table 1**). We observed the association signal in the *LRRC4C* locus across multiple ancestries including NHW ($P=1.8\times 10^{-6}$), HIS ($P=7.6\times 10^{-3}$), and EAS ($P=0.06$) (**Figure 3** and **Table 1**) with the minor allele C (range of minor allele frequencies [MAFs]=0.17-0.33) increasing risk in all ancestries (ORs from 1.11 to 1.14; **Table 1**). In contrast, ancestry-specific evaluation of rs111486601 in the *LHX5-AS1* region revealed the association signal to be driven predominantly by HIS (MAF=0.04, OR=0.44, 95% CI=0.34-0.57, $P=4.8\times 10^{-10}$) (**Figure 4** and **Table 1**).

In addition to these two novel loci, 11 known AD loci were genome-wide significant in cross-ancestry meta-analysis (**Table 1**). Among these, the association signals from *BINI*, *CD2AP*, *PTK2B*, *CLU*, *SHARPIN*, *MS4A6A*, *PICALM*, *ABCA7*, and *APOE* were supported by contributions from at least two ancestry groups with $P<0.05$ (**Supplementary Figures 7-15**).

In the *APOE* $\epsilon 4$ -unadjusted model, of the genome-wide significant SNPs at the 13 loci, two (15%) were GWS and seven (54%) were nominally significant ($P<0.05$) in HIS; one (7.7%) was GWS and three (23%) were nominally significant in EAS; one (7.7%) each were GWS and nominally significant in AFA; and seven (54%) were at least nominally significant in both NHW and HIS indicating the strongest contribution to the signals by NHW (NHW>HIS>EAS>AFA) (**Figure 2**, **Supplementary Figures 7-15**). While sample sizes differed between ancestry groups, marker allele frequencies also varied widely, though directions of association were largely consistent across ancestry groups for most reported loci.

Following up other previously-reported loci reaching genome-wide significance in cross-ancestry analyses (**Supplementary Table 8**), we observe strong associations near but not

attaining GWS at several loci including *SORL1* (rs117618017, $P=9.6\times 10^{-8}$), *ECHDC3* (rs7920721, $P=1.1\times 10^{-7}$), and *ABCA7* (rs115882880, $P=1.0\times 10^{-7}$). Within ancestries, the *PALM2AKAP2*, previously observed in a GWAS of Japanese subjects that is a subset of our EAS sample, was observed only among EAS participants (rs913360, $P=2.7\times 10^{-8}$), and the noted association at *ABCA7* was driven almost exclusively by association in AFA individuals (rs117618017, $P=9.6\times 10^{-8}$) which included subjects from the dataset that originally identified *ABCA7* in AFA. Notably, a variant in the *APOE* region of chromosome 19 near *APOC1*, rs157591, demonstrated GWS associations in AFA ($P=3.3\times 10^{-17}$) and HIS participants ($P=1.7\times 10^{-20}$), but only nominal significance in NHW ($P=6.3\times 10^{-3}$); further adjustment for *APOE* $\epsilon 4$ modestly reduced strength of association in AFA ($P=4.0\times 10^{-14}$), with no association in HIS ($P=0.573$) or NHW ($P=0.237$), suggesting an ancestry-specific association independent of *APOE* $\epsilon 4$ in AFA.

APOE $\epsilon 4$ -Adjusted Model

In cross-ancestry meta-analysis adjusting for *APOE* $\epsilon 4$, (**Supplementary Figure 3** and **Table 2**), rs111486601 near *LHX5-AS1* remained genome-wide significant ($P=1.47\times 10^{-9}$) while rs12576934 near *LRRC4C* showed reduced genome-wide significance ($P=7.13\times 10^{-6}$ (**Table 2**)). Besides the *APOE* $\epsilon 2$ SNP, six known AD loci, including *CRI*, *BINI*, *TREM2*, *MS4A6A*, *PICALM*, and *ABCA7*, remained genome-wide significant when adjusting for the *APOE* $\epsilon 4$ dosage. In addition, in this model a locus within *WNT3* (rs430685; $P=7.4\times 10^{-8}$) near *MAPT* emerged with near genome-wide significance (**Table 2**).

Novel ancestry-specific loci

In the *APOE* $\epsilon 4$ -unadjusted model, ancestry-specific meta-analysis identified one novel genome-wide significant SNP for AD in NHW near *KIAA0825* (rs141408991; OR=0.50,

CI=0.39-0.64, $P=2.9\times 10^{-8}$) (**Table 3**). Under the *APOE* $\epsilon 4$ -adjusted model, ancestry-specific meta-analyses revealed two novel loci in *HIS*, one near *GRB14* (rs73978419; OR=0.044, 95% CI=0.33-0.59, $P=1.3\times 10^{-8}$) and one near *PTPRK* (rs67714619; OR=1.34, 95% CI=1.21-1.48, $P=2.4\times 10^{-8}$) (**Table 3**).

Functional Annotation of Significantly-Associated Multi-Ancestry Loci

The lead variant of the *LRRC4C* locus (rs12576934) lies in the intergenic region 254,788 basepairs upstream from the *LRRC4C* (closest protein-coding gene; negative strand) transcription start site (TSS) and overlaps enhancers in cultured neurons suggesting a potential role in enhancer regulation in tissues/cell types related to AD pathogenesis (**Supplementary Figure 16**). Notably, rs12576934 is a significant splicing quantitative trait locus (sQTL) for *LRRC4C* in brain frontal cortex ($P=5.89\times 10^{-4}$) from the Genotype-Tissue Expression (GTEx) Consortium¹⁶. However, rs12576934 does not show a significant association with *LRRC4C* expression in any brain-tissue related expression QTL (eQTL) data, including GTEx, Metabrain¹⁷, the Microglia Genome Atlas (MiGA)¹⁸, and Accelerating Medicine Partnerships-Alzheimer's Disease (AMP-AD)¹⁹ resources.

For the *LHX5-ASI* locus, the lead variant (rs111486601) is located 170,842 base pairs upstream of the *LHX5* TSS (closest protein-coding gene; negative strand). Multiple variants in linkage disequilibrium (LD; estimated using 1000 Genomes NHW populations²⁰⁻²²) with rs111486601 overlap ROADMAP²³ ChromHMM²⁴ brain enhancers in neuronal culture cells, hippocampus middle region dorsolateral prefrontal cortex, as well as blood enhancers in primary B and NK cells, suggesting potential regulatory roles in immune cell types and brain regions that are known to be related to AD. The variant rs111486601 overlaps and potentially disrupts multiple transcription factor binding sites (TFBS) as predicted by Hypergeometric Optimization

of Motif Enrichment (HOMER²⁵). Given that rs111486601 is rare in NHW (MAF=0.0006), it is not presently observed in any QTL database (GTEx, Metabrain, MiGA, or AMP-AD), as these databases have been generated using common European ancestry variants.

Differential Expression Analysis of Significantly Associated Loci

Of eight genes flanking intergenic SNPs or containing GWS SNPs from the five novel loci, *LRRC4C* and *KIAA0825* were differentially expressed between autopsy-confirmed AD brains and brains of cognitively-intact decedents with $P < 0.05$ in secondary analysis of previously-reported²⁶ differential expression analyses using autopsied Framingham Heart Study (FHS, **Supplementary Table 9**) brains (strongest association at *LRRC4C*: $\log_2FC = -0.01$, $P = 8.8 \times 10^{-4}$), while only expression of *LRRC4C* was significantly associated with Braak stage in FHS in autopsied AD brains (best association at *LRRC4C*: $\beta = -0.11$, $P = 4.7 \times 10^{-3}$).

Pathway analyses

We performed pathway enrichment analyses including genes containing or flanking suggestively associated SNPs ($P < 10^{-6}$) from the cross-ancestry meta-analysis. We selected 86 and 60 genes for *APOE* $\epsilon 4$ -unadjusted and -adjusted models, respectively. For both models, amyloid-beta related pathways were the top-ranked pathway, indicating that the relevance of this pathway in cross-ancestry meta-analysis was unaffected by *APOE* $\epsilon 4$ adjustment. In the *APOE* $\epsilon 4$ -unadjusted model, lipid transport, endocytosis, and classical complement pathways were in addition significantly associated ($P_{\text{adjusted}} < 0.05$) (**Supplementary Table 10a**). Examining the *APOE* $\epsilon 4$ -adjusted model, classical complement and phospholipid efflux pathways were now more significantly associated and ranked higher than chylomicron remnant clearance, cholesterol, and endocytosis pathways with lower significance (**Supplementary Table 10b**).

Employing the ancestry-specific GWAS results from the two models, we determined pathways shared across ancestry groups (**Supplementary Table 11**). Among the significant pathways in each ancestry ($P_{\text{adjusted}} < 0.05$) from the *APOE* $\epsilon 4$ -unadjusted model, seven pathways were shared across all four ancestries related to lipid metabolism pathways (**Supplementary Figure 17a**). In the *APOE* $\epsilon 4$ -adjusted model no pathways with $P_{\text{adjusted}} < 0.05$ were shared across ancestries (**Supplementary Figure 17b**).

DISCUSSION

In the largest cross-ancestry GWAS meta-analysis in AD to date, we identified two novel genome-wide cross-ancestry associations near *LRRC4C* and *LHX5-AS1*, and three ancestry-specific genome-wide significant loci near *KIAA0825* (NHW), and *GRB14* and *PTPRK* (HIS). Functional annotation follow-up revealed the *LRRC4C* variant's potential regulatory role in enhancer regulation in tissues and cell types related to AD pathogenesis, and the involvement of the *LHX5-AS1* variant in regulatory roles in immune cell types and brain regions. *In silico* differential expression analyses across brain tissues suggested differential expressions of *LRRC4C* and *KIAA0825* between AD and control brains and association of *LRRC4C* expression with Braak stage. Pathway analyses implicated pathways associated with amyloid metabolism, cholesterol transport, and inflammation, consistent with previous pathway-based findings in AD.

While the available AD GWAS data from non-European ancestry groups continue to be dwarfed by the sample sizes of AD GWAS in European ancestry subjects, our analyses demonstrate the power of multi-ancestry datasets. Of particular interest is the significant association at the *SHARPIN* locus in our study. The *SHARPIN* locus was first observed in a study of 111,326 clinically-diagnosed and 'proxy' AD cases and 677,663 controls individuals of European ancestry (rs34173062, MAF=0.081, OR=1.13, $P=1.7 \times 10^{-6}$) and later confirmed in

much larger sample sizes^{4,27,28}. While NHW participants in this study had similar MAF (0.086 here vs. 0.081) and similar effect size (OR=1.19 here vs. 1.13), the much larger effect size in HIS participants (OR_{HIS}=1.37; MAF_{HIS}=0.057) ensured sufficient power to detect a GWS cross-ancestry association in just 56,241 subjects, only 7.1% the sample size of Bellenguez et al., an astonishing reflection on the unique power leveraging diverse ancestries can provide.

Among the novel loci identified in cross-ancestry analyses, both *LRRC4C* and *LHX5-AS1* are potential biological candidates for roles in AD. *LRRC4C* encodes leucin-rich repeat (LRR) containing adhesion molecules, which are key organizers of inhibitory and excitatory synapses. Mutations within the gene have been implicated in neurodevelopmental disorders, such as autism²⁹ and intellectual disability³⁰. *LRRC4C* variants with suggestive associations with CSF b-site APP cleaving enzyme (BACE) have been previously discovered in ADNI³¹. Additionally, one study used *LRRC4C* knock-out mice in an experimental multiple sclerosis model and found a neuron-protective role for *LRRC4C*, concluding that the ectopic expression of *LRRC4C* protected neurons from immune damage³². Associated variants in the *LRRC4C* locus are significantly associated with sQTL for *LRRC4C* in GTEx brain frontal cortex, and fall in a regulatory region that are notably enhancers in neuron tissue³³, with transcription factor (TF) Chromatin ImmunoPrecipitation Sequencing (ChIP-Seq) experiments showing the region overlapping our index variant as being a target of Srebf1 in exocrine gland, epithelium and mammary gland tissues. Srebf1 is a transcriptional activator required for lipid homeostasis and has been identified as a proneural transcription factor in radial glia³⁴. Variants of *SREBF1* influence AD risk by moderating the deleterious effect of the *APOE* ε4 allele³⁵.

LHX5-AS1 is an antisense RNA gene, which is complementary to the mRNA *LHX5* with which it hybridizes and blocks its translation into protein. *LHX5* encodes LIM homeobox 5,

which is essential for the regulation of precursor cell proliferation. This gene controls neuronal differentiation and migration during hippocampal development. *LHX5* and *LHX5-AS1* are similarly expressed in various regions of the adult central nervous system including hypothalamus, spinal cord, cerebellum, basal ganglia, and cerebellar hemisphere. Significantly associated variants for this locus fall in a regulatory region, for example, bivalent enhancers in hematopoietic multipotent progenitor cells and brain³³. Our specific index variant is an enhancer in blood and a transcription variant in neural progenitor cells³³. Variants in 12q24 have previously been associated with hippocampal volume³⁶. This novel locus is ~360 kb away from the recently-reported locus at *TPCNI*⁴.

Notably, most of the novel loci identified in ancestry-specific analyses act in biologically plausible pathways. The protein encoded by *Grb14* functions as a negative modulator of insulin receptor activity (IR) activity. Both insulin resistance and type 2 diabetes (T2D) and have been implicated in AD by a large body of epidemiological, neuropathological, and experimental studies³⁷. Brain tissue from individuals with AD show major abnormalities in insulin signaling and increased presence of disease-specific pathological lesions, neurodegeneration, and neuronal vulnerability^{37,38}. In structural and functional neuroimaging studies, T2D and insulin resistance are associated with white increased burden of white matter lesions, decreased hippocampal volume, regional cerebral blood flow and oxygenation³⁹⁻⁴³. *PTPRK* encodes a member of the protein tyrosine phosphatase (PTP) family regulating a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. Variants in *PTPRK* were recently found to be associated with reaction time in a GWAS on cognitive function in 300,486 individuals of European ancestry⁴⁴. *KIAA0825* encodes a protein of largely unknown

function; however, it is differentially expressed in AD vs. control in brain RNAseq data (see URL below).

Leveraging GWAS on diverse ancestries, here we observed evidence for novel loci not seen in prior multi-ancestry or large NHW-only studies. Especially salient is the association at the *SHARPIN* locus, first observed as a dementia locus in a single-ancestry NHW GWAS almost 13 times larger than the current study, and observed here with far fewer samples (rs34173062, $P=1.81\times 10^{-9}$).

While this study yielded several novel AD susceptibility loci, the fewer non-European ancestry samples relative to European ancestry samples (57.2% of participants) remains a limitation. This constrains the identification of rare variants and novel ancestry-specific loci in highly admixed groups including AFA and HIS, where heterogeneity in levels of European, African, and Amerindian admixture may strongly limit statistical power. Future work planned for these data includes global and local admixture analyses to provide detailed characterization of patterns of admixture and adjust for these positional and ancestry-specific background differences. While more non-European ancestry AD GWAS are valuable for cross-ancestry comparisons of AD genetic risk profiles, even modest amounts of diverse data tremendously boost our ability to detect novel AD susceptibility loci.

METHODS

Variant- and sample-level quality control (QC). We performed QC on individual ADGC datasets using a multi-step pipeline with key functions implemented in PLINK v1.9⁴⁵⁻⁴⁷. All datasets included in analysis included only cases that met either NINCDS-ADRDA⁴⁸ or NIA-AA⁴⁹ criteria for clinical diagnosis of AD and had an age-at-onset >60 years or had autopsy-

confirmation of late-onset AD pathology; controls/non-cases (“cognitively-normal elders”, CNEs) were individuals with a mini-mental status examination (MMSE) >26 or modified mini-mental status examination (3MS) score >87 at most recent exam and/or were reported to be cognitively intact at time of death (details in **Supplementary Note 1**). We identified and excluded low-quality variants and samples after re-estimating all quality metrics following an initial filter excluding variants with a genotype missingness rate of $>10\%$. Variant-level QC filters implemented thereafter included exclusions of (a) SNPs with call rates below 98% for Illumina and 95% for Affymetrix panels; (b) SNPs with departure from Hardy-Weinberg Equilibrium (HWE) of $P < 10^{-6}$ among controls for variants of $MAF > 0.01$; and (c) SNPs with informative missingness by case-CNE status of $P < 10^{-6}$. For sample-level QC, samples were excluded if (a) the individual genotyping call rate was $<95\%$; (b) if X chromosome heterozygosity indicated inconsistency between predicted and reported sex; or (c) if population substructure analyses (described below) indicated the sample did not cluster with samples in its reported ancestry grouping when compared against multi-ancestry data from the 1000 Genomes (1kG) Phase 3 reference panel. For examples, reported NHW samples were expected to cluster with 1kG European ancestry sample groups while reported AFA samples being admixed were expected to cluster between and around 1kG European and African ancestry sample groups.

Relatedness Checks. Relatedness was assessed using the “--genome” function of PLINK v1.9. Using a common set of $\sim 20,000$ linkage disequilibrium (LD)-pruned SNPs sampled from among genotyped variants across ancestry groups, $\hat{\pi}$ (the proportion of alleles shared IBD) was estimated across all pairs of participants across all ADGC datasets. Among pairs of participants with no known familial relationships, one sample was excluded among pairs with $\hat{\pi} > 0.95$ if phenotype and covariate data were identical, otherwise both samples were excluded; among all

pairs with $\hat{\pi} > 0.4$ but less than 0.95, one sample was kept giving preference to cases over CNEs, age (earlier age-at-onset among case pairs, later age-at-exam among CNE pairs). Pairs of relatives were dropped from family datasets if $\hat{\pi}$ differed substantially from expectation based on their reported relationships.

Population substructure. To identify outlier samples within each dataset with ancestry group, we performed a principal components analysis (PCA) using ‘smartpca’ in EIGENSOFT^{50,51} on the subset of ~20,000 LD-pruned SNPs used for relatedness checks on genotypes from all samples within each individual dataset and from the 1kG Phase 3 reference panels. Individuals not clustering with their reported ancestry groups (or between reported ancestry groups for admixed subjects) were excluded from analysis when including 1kG groups. To account for the effects of population substructure in our analysis, a second PCA was performed using only the remaining individuals in each dataset. Principal components (PCs) 1-10 were examined for association with AD case-control status and eigenvector loading, and only PCs showing nominal association with AD ($P < 0.05$) and eigenvector loadings > 3 were used in covariate adjustment for populations substructure (average number of PCs used is 3; range: 2-4).

TOPMed Imputation. For each dataset, SNPs not directly genotyped were imputed on the Trans-Omics for Precision Medicine (TOPMed) Imputation Server (TIS)⁵² using samples of all ancestries available on the release 5 (R5) reference panel⁵³, which includes 308,107,085 SNPs observed on 194,512 haplotypes (from 97,256 participants), all with an estimated minor allele count (MAC) ≥ 5 and observed in samples from at least two separately-ascertained data sources. Phasing on the TIS was done with EAGLE⁵⁴, while imputation was performed using Minimac4⁵⁵. Quality of imputation for all variants was assessed using R^2 for imputation quality, although all variants were retained and not filtered prior to analysis. Following imputation and

analysis, SNPs of all frequency were filtered using a conservative quality threshold, $R^2 \geq 0.8$, to assure high quality of rare variants with $MAF \leq 0.01$. Analysis of SNP imputation quality by bin of MAF revealed that more than 80% of variants of $MAF > 0.0005$ had $R^2 \geq 0.8$; among variants with $MAF \leq 0.0005$, approximately 50% of variants had $R^2 \geq 0.8$ in most datasets with $n > 1,000$ participants. After association analyses at several cross-dataset and within-dataset filtering thresholds, reported analyses include only variants of $R^2 \geq 0.8$ within each dataset for the purpose of noise reduction. Genotyped and imputed variants were all mapped to the GRCh138/hg38 human genome build.

Single-variant Association Analysis and Within-Ancestry Meta-analysis for Common Variants ($MAF > 0.01$). Single variant-based association analysis on datasets of unrelated cases and CNEs were performed in SNPTEST⁵⁶ using score-based logistic regression under an additive model with covariate adjustment for PCs, age (defined as age-at-onset for cases and age-at-last exam for CNEs), sex, and in certain datasets, additional adjustment for study-specific indicator variables (“APOE-unadjusted”; Model 1). A second model (“APOE-adjusted”; Model 2) included covariate adjustment for dosage of APOE $\epsilon 4$ (0/1/2 copies), which is commonly observed as an effect modifier. Family-based datasets were analyzed using GMMAT, an R package for performing association tests using generalized linear mixed models (GLMMs). These GLMMs allow for both a binary outcome and adjustment for relatedness via a genetic relationship matrix (GRM). Score tests were performed for each genetic variant assuming an additive model with fixed effect covariate adjustment for PCs, age (defined as age-at-onset for cases and age-at-last exam for CNEs), sex and random effect adjustment for the GRM (calculated using GEMMA) in the family-based datasets. After association analysis on imputed data, variants with regression coefficient of $|\beta| > 5$ and any erroneous estimates (negative standard

errors or P -values equal to 0 or 1) were excluded from further analysis. Within-study association results for variants common ($MAF > 0.01$) to at least one study were meta-analyzed using a fixed-effects approach with inverse variance-weighting in METAL⁵⁷.

Single-variant Association Analysis and Within-Ancestry Meta-analysis for Rare Variants ($MAF \leq 0.01$). Rare variant association and meta-analysis was performed for individual variants using the SeqMeta⁵⁸ package in R⁵⁹. SeqMeta performs a score-based logistic regression, estimating scores in individuals using ‘prepScores()’ and performing meta-analysis using ‘singleSNPMeta()’. Family-based datasets were analyzed using GMMAT as described previously for common variants and no datasets with fewer than 100 cases and/or CNEs were analyzed. As in common variant analyses, models evaluated included covariate adjustment for PCs. As for common variants, any SNPs with a regression coefficient of $|\beta| > 5$ and any erroneous estimates were excluded from further analysis after meta-analysis of imputed rare variants.

Single-variant Cross-Ancestry Meta-Analysis. All cross-ancestry meta-analyses were performed using the Han-Eskin random-effects (RE_{HE}) model as implemented in METASOFT⁶⁰, which is optimized for the detection of cross-ancestry associations in the presence of effect heterogeneity between ancestry groups. The RE_{HE} model has similar power to a fixed-effects model when effect heterogeneity between ancestry groups is modest. Cross-ancestry meta-analyses incorporated within-ancestry genome-wide summary statistics from the single variant fixed-effects meta-analyses described above for NHW, AFA, HIS, and EAS ancestry groups (SNPTEST/GMMAT METAL for common variants [$MAF \geq 0.01$]; SeqMeta/GMMAT for rare variants [$MAF < 0.01$]). In the primary cross-ancestry analyses, all variants with a within-ancestry $MAF > 0.01$ in at least one dataset were incorporated into analyses.

Functional Annotation of Significantly Associated Loci. We used all annotations in Functional genomics repository (FILER)⁶¹ for our analyses. To reveal potential biological functions of the variants, experimental studies have shown that matching tissues/cell types to the phenotype of interest is one of the keys to success. Thus, we focused our analyses on the brain-related tracks harmonized in FILER. These brain-related tracks originated from ROADMAP²³ (for enhancer and active histone marks), Encyclopedia of DNA Elements (ENCODE⁶²; active histone marks) and HOMER²⁵ (predicted TFBSs). We annotated the five-novel genome-wide significant signals (cross ancestry and ancestry-specific results) using brain-related tracks harmonized in FILER. By annotating variants with these various functional genomics data, we identified variants with converging functional evidence and determined which variants had a higher chance of being functional in the brain.

Differential Expression Analysis of Significantly Associated Loci. We followed up SNPS with genome-wide significant associations (GWS; $P < 5 \times 10^{-8}$). If the GWS SNP is intergenic, we selected closest genes of the SNP. If the GWS SNP resides in the gene, we selected the gene. The selected genes were assessed for differential expression between AD and control brains from prefrontal cortex tissue specimens of 208 participants (64 autopsy-confirmed AD cases and 129 controls) of the Framingham Heart Study (FHS) and Boston University Alzheimer's Disease Center (BUADC). Details of diagnosis, data cleaning, and analysis methods were previously reported^{26,63}. In brief, differential gene expression between AD and control brains was performed using the LIMMA^{64,65} software. Expression of a gene was compared in AD and control brains using linear regression models including the log₂-transformed normalized expression values and terms for age at death (AAD), sex, and RNA integrity number (RIN). We also evaluated associations of gene expression for Braak staging for neurofibrillary tangles and the Consortium

to Establish a Registry for Alzheimer Disease (CERAD) semi-quantitative criteria for neuritic plaques (CERAD Score)⁶⁶. Values for each trait were adjusted for AAD and sex, and the residuals were rank-transformed as previously described⁶⁷. Association of \log_2 -transformed expression levels for each rank-transformed neuropathological trait was evaluated using linear regression models that adjusted for RIN in the FHS/BUADC dataset.

Pathway Analysis. For pathway analysis, we selected flanking genes of suggestive SNPs with $P < 10^{-6}$ from cross-ancestry meta-analysis and each within-ancestry meta-analysis. We conducted pathway analysis using GO Biological Process in the EnrichR program⁶⁸. For cross-ancestry signals, we compared significantly enriched pathways after FDR corrected P -value ($P_{\text{adjusted}} < 0.05$) between *APOE*-unadjusted and -adjusted models. For each analysis model, we created Venn diagrams of pathways with $P_{\text{adjusted}} < 0.05$ from each ancestry. We reported both unique and shared pathways across different ancestry populations.

ACKNOWLEDGEMENTS

The National Institutes of Health, National Institute on Aging (NIH-NIA) supported this work through the following grants: ADGC, U01 AG032984, RC2 AG036528; Samples from the National Cell Repository for Alzheimer's Disease (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA), were used in this study. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible; Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689); GCAD, U54 AG052427; NACC, U01 AG016976; NIA LOAD (Columbia University), U24AG056270; Banner Sun Health Research Institute P30 AG019610; Boston University, P30 AG013846, U01 AG10483, R01 CA129769, R01 MH080295, R01 AG017173, AG025259, R01 AG048927, RF1 AG057519, R01AG33193, R01 AG009029; Columbia University, P30AG066462, R01 AG072474, R01 AG067501; Duke University, P30 AG028377, AG05128; Emory University, AG025688; Group Health Research Institute, U01 AG006781, U01 HG004610, U01 HG006375, U01 HG008657; Indiana University, P30 AG10133, R01 AG009956, RC2 AG036650; Johns Hopkins University, P50 AG005146, R01 AG020688; Massachusetts General Hospital, P50 AG005134, P30 AG062421; Mayo Clinic, P50 AG016574, R01 AG032990, KL2 RR024151; Mount Sinai School of Medicine, P50 AG005138, P01 AG002219; New York University, P30 AG08051, UL1 RR029893, 5R01AG012101, 5R01AG022374, 5R01AG013616, 1RC2AG036502, 1R01AG035137; North Carolina A&T University, P20 MD000546, R01 AG28786-01A1; Northwestern University, P30 AG013854; Oregon Health & Science University, P30 AG008017, R01 AG026916; Rush University, P30

AG010161, R01 AG019085, R01 AG15819, R01 AG17917, R01 AG030146, R01 AG01101, RC2 AG036650, R01 AG22018; TGen, R01 NS059873; University of Alabama at Birmingham, P50 AG016582; University of Arizona, R01 AG031581; University of California, Davis, P30 AG010129; University of California, Irvine, P50 AG016573; University of California, Los Angeles, P50 AG016570; University of California, San Diego, P50 AG005131; University of California, San Francisco, P50 AG023501, P01 AG019724; University of Kentucky, P30 AG028383, AG05144; University of Michigan, P50 AG008671, P30 AG053760; University of Pennsylvania, P30 AG010124; University of Pittsburgh, P50 AG030653, P50 AG041718, P50 AG064877, P30 AG066468; University of Southern California, P50 AG005142; University of Texas Southwestern, P30 AG012300; University of Miami, R01 AG070864, AG052410, AG074527 and U01 AG058654, AG057659, AG062943, AG066767, AG076482 AND U19 AG074865; University of Washington and Kaiser Foundation Research Institute, P50 AG005136, R01 AG042437, P30 AG066509, U19 AG066567; University of Wisconsin, P50 AG033514; Vanderbilt University, R01 AG019085; and Washington University, P50 AG005681, P01 AG03991, P01 AG026276. The Kathleen Price Bryan Brain Bank at Duke University Medical Center is funded by NINDS grant # NS39764, NIMH MH60451 and by Glaxo Smith Kline. Support was also from the Alzheimer's Association (LAF, IIRG-08-89720; MP-V, IIRG-05-14147), the US Department of Veterans Affairs Administration, Office of Research and Development, Biomedical Laboratory Research Program, and BrightFocus Foundation (M.P.-V., A2111048). P.S.G.-H. is supported by Wellcome Trust, Howard Hughes Medical Institute, and the Canadian Institute of Health Research. Genotyping of the TGEN2 cohort was supported by Kronos Science. The TGen series was also funded by NIA grant AG041232 to AJM and MJH, The Banner Alzheimer's Foundation, The Johnnie B. Byrd Sr.

Alzheimer's Institute, the Medical Research Council, and the state of Arizona and also includes samples from the following sites: Newcastle Brain Tissue Resource (funding via the Medical Research Council, local NHS trusts and Newcastle University), MRC London Brain Bank for Neurodegenerative Diseases (funding via the Medical Research Council), South West Dementia Brain Bank (funding via numerous sources including the Higher Education Funding Council for England (HEFCE), Alzheimer's Research Trust (ART), BRACE, Alzheimer's Brain Bank UK, and Development and Alumni Relations (DARO) Office, as well as North Bristol NHS Trust Research and Innovation Department and DeNDRoN), The Netherlands Brain Bank (funding via numerous sources including Stichting MS Research, Brain Net Europe, Hersenstichting Nederland Breinbrekend Werk, International Parkinson Fonds, Internationale Stichting Alzheimer Onderzoek), Institut de Neuropatologia, Servei Anatomia Patologica, Universitat de Barcelona. ADNI data collection and sharing was funded by the National Institutes of Health Grant U01 AG024904 and Department of Defense award number W81XWH-12-2-0012. Funding for Saarland University was provided by the German Federal Ministry of Education and Research (BMBF), grant number 01GS08125 to Matthias Riemenschneider. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research;

Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Additional salary and analytical support were provided by NIA grants R01 AG054060 and RF1 AG061351. We thank Drs. D. Stephen Snyder and Marilyn Miller from NIA who are *ex-officio* ADGC members.

URLs.

Agora AD Knowledge Portal entry for KIAA0825 expression across brain regions:

<https://agora.adknowledgeportal.org/genes/ENSG00000185261/evidence/rna>

References

1. Alzheimer's Association. 2023 Alzheimer's disease facts and figures. *Alzheimers Dement* (2023).
2. Kunkle, B.W. *et al.* Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. *Nat Genet* **51**, 414-430 (2019).
3. Jansen, I.E. *et al.* Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nat Genet* **51**, 404-413 (2019).
4. Bellenguez, C. *et al.* New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet* **54**, 412-436 (2022).
5. Wightman, D.P. *et al.* A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. *Nat Genet* **53**, 1276-1282 (2021).
6. Asgari, S. *et al.* A positively selected FBN1 missense variant reduces height in Peruvian individuals. *Nature* **582**, 234-239 (2020).
7. Sigma Type 2 Diabetes Consortium *et al.* Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. *JAMA* **311**, 2305-14 (2014).
8. Moltke, I. *et al.* A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. *Nature* **512**, 190-3 (2014).
9. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat Genet* **54**, 573-580 (2022).
10. Koyama, S. *et al.* Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. *Nat Genet* **52**, 1169-1177 (2020).
11. Chen, M.H. *et al.* Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. *Cell* **182**, 1198-1213 e14 (2020).
12. Huang, H. *et al.* Fine-mapping inflammatory bowel disease loci to single-variant resolution. *Nature* **547**, 173-178 (2017).
13. Laufer, V.A. *et al.* Genetic influences on susceptibility to rheumatoid arthritis in African-Americans. *Hum Mol Genet* **28**, 858-874 (2019).
14. Marquez-Luna, C., Loh, P.R., South Asian Type 2 Diabetes, C., Consortium, S.T.D. & Price, A.L. Multiethnic polygenic risk scores improve risk prediction in diverse populations. *Genet Epidemiol* **41**, 811-823 (2017).
15. Mathieson, I. & Scally, A. What is ancestry? *PLoS Genet* **16**, e1008624 (2020).
16. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* **369**, 1318-1330 (2020).
17. de Klein, N. *et al.* Brain expression quantitative trait locus and network analyses reveal downstream effects and putative drivers for brain-related diseases. *Nat Genet* **55**, 377-388 (2023).
18. Lopes, K.P. *et al.* Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies. *Nat Genet* **54**, 4-17 (2022).
19. Sieberts, S.K. *et al.* Large eQTL meta-analysis reveals differing patterns between cerebral cortical and cerebellar brain regions. *Sci Data* **7**, 340 (2020).
20. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation. *Nature* **526**, 68-74 (2015).
21. Mallick, S. *et al.* The Simons Genome Diversity Project: 300 genomes from 142 diverse populations. *Nature* **538**, 201-206 (2016).
22. Bergstrom, A. *et al.* Insights into human genetic variation and population history from 929 diverse genomes. *Science* **367**(2020).
23. Roadmap Epigenomics Consortium *et al.* Integrative analysis of 111 reference human epigenomes. *Nature* **518**, 317-30 (2015).
24. Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and characterization. *Nat Methods* **9**, 215-6 (2012).
25. Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* **38**, 576-89 (2010).

26. Panitch, R. *et al.* Integrative brain transcriptome analysis links complement component 4 and HSPA2 to the APOE epsilon2 protective effect in Alzheimer disease. *Mol Psychiatry* **26**, 6054-6064 (2021).
27. Schwartzenuber, J. *et al.* Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer's disease risk genes. *Nat Genet* **53**, 392-402 (2021).
28. de Rojas, I. *et al.* Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. *Nat Commun* **12**, 3417 (2021).
29. Jiang, Y.H. *et al.* Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. *Am J Hum Genet* **93**, 249-63 (2013).
30. Sangu, N. *et al.* A 7q31.33q32.1 microdeletion including LRRC4 and GRM8 is associated with severe intellectual disability and characteristics of autism. *Hum Genome Var* **4**, 17001 (2017).
31. Hu, H. *et al.* Genome-wide association study identified ATP6V1H locus influencing cerebrospinal fluid BACE activity. *BMC Med Genet* **19**, 75 (2018).
32. Zhang, Y. *et al.* LRRC4 functions as a neuron-protective role in experimental autoimmune encephalomyelitis. *Mol Med* **27**, 44 (2021).
33. Boyle, A.P. *et al.* Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res* **22**, 1790-7 (2012).
34. Toledo, E.M. *et al.* Srebf1 Controls Midbrain Dopaminergic Neurogenesis. *Cell Rep* **31**, 107601 (2020).
35. Spell, C. *et al.* SREBP-1a polymorphism influences the risk of Alzheimer's disease in carriers of the ApoE4 allele. *Dement Geriatr Cogn Disord* **18**, 245-9 (2004).
36. Bis, J.C. *et al.* Common variants at 12q14 and 12q24 are associated with hippocampal volume. *Nat Genet* **44**, 545-51 (2012).
37. Arnold, S.E. *et al.* Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. *Nat Rev Neurol* **14**, 168-181 (2018).
38. Moloney, A.M. *et al.* Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. *Neurobiol Aging* **31**, 224-43 (2010).
39. den Heijer, T. *et al.* Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. *Diabetologia* **46**, 1604-10 (2003).
40. Gold, S.M. *et al.* Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. *Diabetologia* **50**, 711-9 (2007).
41. Tan, Z.S. *et al.* Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study. *Diabetes Care* **34**, 1766-70 (2011).
42. Willette, A.A., Modanlo, N., Kapogiannis, D. & Alzheimer's Disease Neuroimaging, I. Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease. *Diabetes* **64**, 1933-40 (2015).
43. Hoscheidt, S.M. *et al.* Insulin resistance is associated with lower arterial blood flow and reduced cortical perfusion in cognitively asymptomatic middle-aged adults. *J Cereb Blood Flow Metab* **37**, 2249-2261 (2017).
44. Davies, G. *et al.* Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. *Nat Commun* **9**, 2098 (2018).
45. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* **81**, 559-75 (2007).
46. Chang, C.C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).
47. Chang, C.C. Data Management and Summary Statistics with PLINK. *Methods Mol Biol* **2090**, 49-65 (2020).

48. McKhann, G. *et al.* Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* **34**, 939-44 (1984).
49. McKhann, G.M. *et al.* The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**, 263-9 (2011).
50. Price, A.L. *et al.* Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* **38**, 904-9 (2006).
51. Patterson, N., Price, A.L. & Reich, D. Population structure and eigenanalysis. *PLoS Genet* **2**, e190 (2006).
52. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* **48**, 1284-1287 (2016).
53. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* **590**, 290-299 (2021).
54. Loh, P.R. *et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nat Genet* **48**, 1443-1448 (2016).
55. Fuchsberger, C., Abecasis, G.R. & Hinds, D.A. minimac2: faster genotype imputation. *Bioinformatics* **31**, 782-4 (2015).
56. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat Genet* **39**, 906-13 (2007).
57. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-1 (2010).
58. Voorman, A., Brody, J., Chen, H., Lumley, T. & Davis, B. seqMeta: an R package for meta-analyzing region-based test of rare DNA variants. (2013).
59. R Core Team. R: A language and environment for statistical computing. . (R Foundation for Statistical Computing, Vienna, Austria, 2022).
60. Han, B. & Eskin, E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. *Am J Hum Genet* **88**, 586-98 (2011).
61. Kuksa, P.P. *et al.* FILER: a framework for harmonizing and querying large-scale functional genomics knowledge. *NAR Genom Bioinform* **4**, lqab123 (2022).
62. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57-74 (2012).
63. Panitch, R. *et al.* Blood and brain transcriptome analysis reveals APOE genotype-mediated and immune-related pathways involved in Alzheimer disease. *Alzheimers Res Ther* **14**, 30 (2022).
64. Ritchie, M.E. *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* **43**, e47 (2015).
65. Phipson, B., Lee, S., Majewski, I.J., Alexander, W.S. & Smyth, G.K. Robust Hyperparameter Estimation Protects against Hypervariable Genes and Improves Power to Detect Differential Expression. *Ann Appl Stat* **10**, 946-963 (2016).
66. Mirra, S.S. *et al.* The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* **41**, 479-86 (1991).
67. Jun, G. *et al.* EPHA2 is associated with age-related cortical cataract in mice and humans. *PLoS Genet* **5**, e1000584 (2009).
68. Chen, E.Y. *et al.* Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* **14**, 128 (2013).

Table 1. Summary statistics for identified loci reaching genome-wide statistical significance in cross-ancestry meta-analyses of genome-wide associations estimated with covariate adjustment for age-at-onset (cases)/age-at-last-exam (controls), sex, and PCs for population substructure.

Variant	Chr	Basepair	Nearest Gene	Ref/ Eff Alleles	Cross-Ancestry		AFA			EAS			HIS		NHW			
					OR (95% CI)	P	EAf	OR (95% CI)	P	EAf	OR (95% CI)	P	EAf	OR (95% CI)	P	EAf	OR (95% CI)	P
Previous genome-wide-significant loci still reaching significance																		
rs679515	1	207577223	<i>CR1</i>	T/C	1.14 (1.10-1.19)	5.76E-12	0.043	1.11 (0.89-1.38)	0.356	0.059	1.66 (0.70-3.93)	0.245	0.121	1.07 (0.96-1.2)	0.232	0.203	1.16 (1.11-1.20)	6.92E-12
rs6733839	2	127135234	<i>BIN1</i>	C/T	1.12 (1.05-1.2)	7.18E-26	0.398	1.13 (1.04-1.23)	0.00315	0.348	0.99 (0.83-1.18)	0.940	0.407	1.08 (1.00-1.16)	0.0422	0.402	1.20 (1.16-1.24)	4.86E-25
rs75932628	6	41161514	<i>TREM2</i>	C/T	1.44 (0.47-4.4)	1.66E-12	0.001	0.66 (0.18-2.43)	0.532	NA	NA	NA	NA	NA	NA	0.007	2.18 (1.77-2.69)	2.39E-13
rs1385742	6	47627419	<i>CD2AP</i>	A/T	1.10 (1.06-1.14)	7.59E-10	0.422	1.07 (0.98-1.16)	0.133	0.339	1.80 (1.02-3.18)	0.0433	0.366	1.10 (1.02-1.19)	0.0175	0.369	1.10 (1.06-1.14)	3.75E-8
rs2741342	8	27472579	<i>PTK2B</i>	C/T	0.92 (0.86-0.98)	1.22E-8	0.319	0.97 (0.89-1.05)	0.423	0.387	0.79 (0.66-0.95)	0.0109	0.225	0.98 (0.90-1.07)	0.634	0.225	0.89 (0.86-0.93)	8.18E-9
rs1532278	8	27608798	<i>CLU</i>	T/C	0.92 (0.89-0.95)	3.70E-8	0.199	0.92 (0.83-1.02)	0.0979	0.276	1.00 (0.84-1.20)	0.977	0.29	0.88 (0.81-0.96)	0.00220	0.382	0.92 (0.89-0.96)	5.18E-6
rs34173062	8	144103704	<i>SHARPIN</i>	G/A	1.20 (1.04-1.39)	1.81E-9	0.019	0.91 (0.66-1.28)	0.601	NA	NA	NA	0.055	1.37 (1.16-1.61)	1.88E-4	0.086	1.19 (1.12-1.27)	1.38E-7
rs1582763	11	60254475	<i>MS4A6A</i>	G/A	0.92 (0.86-0.98)	6.76E-14	0.104	1.04 (0.91-1.19)	0.603	0.175	0.96 (0.83-1.12)	0.602	0.306	0.90 (0.83-0.98)	0.0142	0.366	0.88 (0.85-0.91)	3.75E-14
rs1898895	11	86126627	<i>PICALM</i>	T/C	0.89 (0.86-0.91)	1.11E-14	0.13	0.89 (0.78-1.00)	0.0515	0.391	0.87 (0.77-0.97)	0.0128	0.255	0.92 (0.85-1.01)	0.0696	0.313	0.88 (0.85-0.91)	2.97E-12
rs12151021	19	1050875	<i>ABCA7</i>	A/G	1.10 (1.06-1.13)	1.59E-8	0.404	1.04 (0.95-1.13)	0.382	0.434	1.17 (0.74-1.84)	0.505	0.332	1.10 (1.02-1.19)	0.0177	0.338	1.11 (1.07-1.15)	1.33E-7
rs429358	19	44908684	<i>APOE ε4</i>	C/T	3.10 (2.75-3.49)	<1E-320	0.241	2.66 (2.41-2.94)	1.31E-85	0.167	4.94 (4.56-5.36)	1.81E-85	0.209	2.26 (2.06-2.47)	1.49E-71	0.259	3.20 (3.08-3.33)	8.9E-734
rs7412	19	44908822	<i>APOE ε2</i>	C/T	0.54 (0.50-0.60)	3.79E-106	0.104	0.59 (0.52-0.68)	5.65E-14	0.04	0.44 (0.37-0.52)	8.89E-7	0.055	0.67 (0.57-0.78)	7.86E-7	0.058	0.48 (0.45-0.52)	4.35E-86
Novel genome-wide-significant loci																		
rs12576934	11	41714561	<i>LRR4C</i>	C/A	1.12 (1.08-1.16)	5.37E-9	0.127	1.09 (0.96-1.23)	0.194	0.335	1.14 (0.99-1.30)	0.0597	0.206	1.13 (1.03-1.24)	0.00761	0.168	1.11 (1.06-1.16)	1.81E-6
rs111486601	12	113643122	<i>LHX5-AS1</i>	C/T	0.63 (0.32-0.81)	1.06E-8	0.018	1.00 (0.74-1.35)	0.992	NA	NA	NA	0.039	0.44 (0.34-0.57)	4.77E-10	0.001	0.50 (0.16-1.60)	0.245

Table 2. Summary statistics for identified loci reaching genome-wide statistical significance in cross-ancestry meta-analyses of genome-wide associations estimated with covariate adjustment for age-at-onset (cases)/age-at-last-exam (controls), sex, dosage of *APOE* ϵ 4 alleles, and PCs for population substructure.

Variant	Chr	Basepair	Nearest Gene	Ref/ Eff Alleles	Cross-Ancestry		AFA			EAS			HIS		NHW			
					OR (95% CI)	P	EAf	OR (95% CI)	P	EAf	OR (95% CI)	P	EAf	OR (95% CI)	P	EAf	OR (95% CI)	P
Previous genome-wide-significant loci still reaching significance																		
rs679515	1	207577223	<i>CR1</i>	T/C	1.14 (1.04-1.24)	2.24E-11	0.042	1.15 (0.91-1.46)	0.235	0.059	1.56 (0.64-3.82)	0.327	0.122	1.03 (0.92-1.16)	0.572	0.203	1.18 (1.13-1.24)	4.54E-12
rs6733839	2	127135234	<i>BIN1</i>	C/T	1.15 (1.10-1.21)	1.84E-20	0.398	1.16 (1.06-1.27)	9.15E-4	0.347	1.01 (0.84-1.22)	0.890	0.407	1.11 (1.03-1.20)	0.00791	0.402	1.19 (1.14-1.24)	6.20E-18
rs75932628	6	41161514	<i>TREM2</i>	C/T	1.10 (0.21-5.66)	2.08E-11	0.001	0.41 (0.11-1.56)	0.193	--	--	--	--	--	--	0.007	2.25 (1.80-2.81)	1.36E-12
rs10792263	11	60312178	<i>MS4A6A</i>	C/T	1.09 (1.03-1.14)	1.12E-8	0.622	1.02 (0.94-1.12)	0.587	0.716	1 (0.88-1.14)	0.998	0.59	1.13 (1.04-1.22)	0.00235	0.627	1.12 (1.07-1.16)	6.44E-8
rs543293	11	86109035	<i>PICALM</i>	A/G	0.89 (0.86-0.92)	1.88E-10	0.136	0.92 (0.81-1.04)	0.181	0.392	0.88 (0.78-0.99)	0.0326	0.26	0.91 (0.84-1.00)	0.0429	0.32	0.89 (0.85-0.93)	1.78E-8
rs430685	17	46781782	<i>WNT3</i>	T/C	0.89 (0.85-0.93)	7.42E-8	0.137	0.92 (0.81-1.05)	0.229	--	--	--	0.18	0.87 (0.79-0.97)	0.00902	0.223	0.89 (0.85-0.94)	3.14E-6
rs115882880	19	1001778	<i>GRIN3B</i>	C/A	1.23 (0.94-1.59)	1.45E-9	0.101	1.50 (1.32-1.70)	2.45E-10	--	--	--	0.04	1.21 (1.00-1.47)	0.0556	0.003	0.82 (0.53-1.28)	0.392
rs7412	19	44908822	<i>APOE</i> ϵ 2	C/T	0.70 (0.62-0.79)	2.00E-30	0.103	0.73 (0.63-0.85)	4.59E-5	0.04	0.79 (0.49-1.27)	0.331	0.05	0.77 (0.65-0.91)	0.00251	0.059	0.63 (0.58-0.69)	3.67E-26
Novel genome-wide-significant loci																		
rs111486601	12	113643122	<i>LHX5-AS1</i>	C/T	0.57 (0.28-1.17)	1.47E-9	0.017	0.96 (0.71-1.28)	0.767	NA	NA (NA)	NA	0.03	0.40 (0.30-0.52)	9.13E-11	0.001	0.42 (0.14-1.27)	0.124

medRxiv preprint doi: <https://doi.org/10.1101/2023.07.06.23292311>; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 3. Summary statistics for identified loci reaching genome-wide statistical significance in within-ancestry meta-analyses estimated under minimum covariate adjustment (age-at-onset (cases)/age-at-last-exam (controls), sex, and PCs for population substructure) and extended covariate adjustment models (age-at-onset (cases)/age-at-last-exam (controls), sex, dosage of *APOE* ϵ 4 alleles, and PCs for population substructure) for identified loci reaching genome-wide significance.

Variant	Chr	Basepair	Nearest Gene	Ref/ Eff Alleles	Cross-Ancestry		AFA			EAS			HIS		NHW			Ancestry with Signal	Model	
					OR (95% CI)	P	EA	OR (95% CI)	P	EA	OR (95% CI)	P	EA	OR (95% CI)	P	EA	OR (95% CI)			P
rs141408991	5	94163462	<i>KIAA0825</i>	G/A	0.69 (0.28-1.09)	1.23E-7	0.002	0.95 (0.26-1.86)	0.945	--	--	--	--	--	0.006	0.50 (0.39-0.57)	2.91E-8	NHW	<i>APOE</i> ϵ 4-unadjusted	
rs73978419	2	164244154	<i>GRB14</i>	A/G	0.71 (0.46-0.89)	6.74E-7	0.025	0.87 (0.67-1.00)	0.307	--	--	--	0.03	0.44 (0.33-0.51)	1.33E-8	0.402	1.04 (0.83-1.16)	0.750	HIS	<i>APOE</i> ϵ 4-adjusted
6:128041848	6	128041848	<i>PTPRK</i>	T/TTAA	1.04 (0.91-1.11)	6.30E-4	0.613	0.99 (0.91-1.04)	0.894	0.939	0.90 (0.71-1.02)	0.406	0.76	1.34 (1.21-1.41)	2.35E-8	0.837	0.97 (0.93-1.00)	0.241	HIS	<i>APOE</i> ϵ 4-adjusted

medRxiv preprint doi: <https://doi.org/10.1101/2023.07.06.23292311>; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 1. Manhattan plot of cross-ancestry meta-analyses of genome-wide associations estimated with covariate adjustment for age-at-onset (cases)/age-at-last-exam (controls), sex, and PCs for population substructure.




Figure 2. Ancestry comparison plot of the multi-ancestry GWAS associations. The plot displays results for 18 loci associated with AD risk within and across multiple ancestries. Circle size corresponds to the significance level, $-\log_{10}(P\text{-value})$, and circle color represents the significance threshold: red, $P < 5 \times 10^{-8}$; orange, $0.05 > P > 5 \times 10^{-8}$; and blue, $P > 0.05$. Arrows represent the direction of effect of the risk allele, with “up” indicating increased risk and down decreased risk. Asterisks (“*”) indicate the association was found in *APOE* $\epsilon 4$ -adjusted models.




Figure 3. (a) Regional association plots and **(b)** Forest plot for the novel *LRRC4C* locus cross-ancestry and within-ancestry associations with AD depicting all associations within ± 500 kb of the

inter
geni
c
lead
varia
nt,
rs12
5769
34.
(a)





Figure 4. (a) Regional association plots and (b) Forest plot for the novel *LHX5-AS1* locus cross-ancestry and within-ancestry associations with AD depicting all associations within ± 500 kb of the intergenic lead variant, rs111486601.

(a)



(b)





Figure 4. Manhattan plot of cross-ancestry meta-analyses of genome-wide associations estimated with covariate adjustment for age-at-onset (cases)/age-at-last-exam (controls), sex, dosage of the *APOE* $\epsilon 4$ allele, and PCs for population substructure.



Author List

Farid Rajabli^{1,2,*}, Penelope Benchek^{3,*}, Giuseppe Tosto^{4,5,*}, Nicholas Kushch², Jin Sha⁶, Katrina Bazemore⁶, Congcong Zhu⁷, Wan-Ping Lee⁸, Jacob Haut⁶, Kara L. Hamilton-Nelson², Nicholas R. Wheeler^{3,9}, Yi Zhao⁸, John J. Farrell⁷, Michelle A. Grunin³, Yuk Yee Leung⁸, Pavel P. Kuksa⁸, Donghe Li⁷, Eder Lucio da Fonseca², Jesse B. Mez¹⁰, Ellen L. Palmer³, Jagan Pillai¹¹, Richard M. Sherva¹², Yeunjo E. Song^{9,3}, Xiaoling Zhang^{7,13}, Taha Iqbal⁶, Omkar Pathak⁸, Otto Valladares⁸, Amanda B. Kuzma⁸, Erin Abner¹⁴, Perrie M. Adams¹⁵, Alyssa Aguirre¹⁶, Marilyn S. Albert¹⁷, Roger L. Albin^{18,19,20}, Mariet Allen²¹, Lisa Alvarez²², Liana G. Apostolova^{23,24}, Steven E. Arnold²⁵, Sanjay Asthana^{26,27,28}, Craig S. Atwood^{26,27,28}, Gayle Ayres¹⁶, Clinton T. Baldwin⁷, Robert C. Barber²², Lisa L. Barnes^{29,30,31}, Sandra Barral^{4,32,5}, Thomas G. Beach³³, James T. Becker³⁴, Gary W. Beecham², Duane Beekly³⁵, Bruno A. Benitez³⁶, David Bennett^{29,31}, John Bertelson³⁷, Thomas D. Bird^{38,39}, Deborah Blacker^{40,41}, Bradley F. Boeve⁴², James D. Bowen⁴³, Adam Boxer⁴⁴, James Brewer⁴⁵, James R. Burke⁴⁶, Jeffrey M. Burns⁴⁷, Joseph D. Buxbaum^{48,49,50}, Nigel J. Cairns⁵¹, Laura B. Cantwell⁸, Chuanhai Cao⁵², Christopher S. Carlson⁵³, Cynthia M. Carlsson^{28,27}, Regina M. Carney⁵⁴, Minerva M. Carrasquillo²¹, Scott Chasse⁵⁵, Marie-Francoise Chesselet⁵⁶, Nathaniel A. Chin^{26,27}, Helena C. Chui⁵⁷, Jaeyoon Chung⁷, Suzanne Craft⁵⁸, Paul K. Crane⁵⁹, David H. Cribbs⁶⁰, Elizabeth A. Crocco⁶¹, Carlos Cruchaga^{62,63}, Michael L. Cuccaro^{2,1}, Munro Cullum¹⁵, Eveleen Darby⁶⁴, Barbara Davis⁶⁵, Philip L. De Jager⁶⁶, Charles DeCarli⁶⁷, John DeToledo⁶⁸, Malcolm Dick⁶⁹, Dennis W. Dickson²¹, Beth A. Dombroski⁸, Rachelle S. Doody⁶⁴, Ranjan Duara⁷⁰, Nilüfer Ertekin-Taner^{21,71}, Denis A. Evans⁷², Kelley M. Faber⁷³, Thomas J. Fairchild⁷⁴, Kenneth B. Fallon⁷⁵, David W. Fardo⁷⁶, Martin R. Farlow⁷⁷, Victoria Fernandez-Hernandez³⁶, Steven Ferris⁷⁸, Tatiana M. Foroud⁷³, Matthew P. Frosch⁷⁹, Brian Fulton-Howard⁸⁰, Douglas R. Galasko⁴⁵, Adriana Gamboa^{81,82}, Marla Gearing^{83,84}, Daniel H. Geschwind⁵⁶, Bernardino Ghetti⁸⁵, John R. Gilbert^{2,1}, Alison M. Goate⁴⁸, Thomas J. Grabowski^{39,86}, Neill R. Graff-Radford^{21,71}, Robert C. Green⁸⁷, John H. Growdon⁸⁸, Hakon Hakonarson^{89,90}, James Hall²², Ronald L. Hamilton⁹¹, Oscar Harari⁶³, John Hardy^{92,93}, Lindy E. Harrell⁹⁴, Elizabeth Head⁹⁵, Victor W. Henderson^{96,97}, Michelle Hernandez⁶⁸, Timothy Hohman^{98,99}, Lawrence S. Honig⁴, Ryan M. Huebinger¹⁰⁰, Matthew J. Huentelman¹⁰¹, Christine M. Hulette¹⁰², Bradley T. Hyman⁸⁸, Linda S. Hynan^{15,103,104}, Laura Ibanez^{105,106}, Gail P. Jarvik^{107,108}, Suman Jayadev³⁹, Lee-Way Jin¹⁰⁹, Kim Johnson⁶⁸, Leigh Johnson⁸¹, M. Ilyas Kamboh^{110,111,112}, Anna M. Karydas⁴⁴, Mindy J. Katz¹¹³, John S. Kauwe^{114,115}, Jeffrey A. Kaye^{116,117}, C. Dirk Keene¹¹⁸, Aisha Khaleeq⁶⁴, Ronald Kim⁹⁵, Janice Knebl⁸¹, Neil W. Kowall^{10,119}, Joel H. Kramer¹²⁰, Walter A. Kukull¹²¹, Frank M. LaFerla¹²², James J. Lah¹²³, Eric B. Larson¹²⁴, Alan Lerner³, James B. Leverenz¹¹, Allan I. Levey¹²³, Andrew P. Lieberman¹²⁵, Richard B. Lipton¹¹³, Mark Logue^{7,126,127}, Oscar L. Lopez³⁴, Kathryn L. Lunetta¹³, Constantine G. Lyketsos¹²⁸, Douglas Mains^{81,82}, Flanagan E. Margaret^{129,130}, Daniel C. Marson⁹⁴, Eden R R. Martin^{2,1}, Frank Martiniuk¹³¹, Deborah C. Mash¹³², Eliezer Masliah^{45,133}, Paul Massman⁶⁴, Arjun Masurkar⁷⁸, Wayne C. McCormick⁵⁹, Susan M. McCurry¹³⁴, Andrew N. McDavid⁵³, Stefan McDonough¹³⁵, Ann C. McKee^{10,136}, Marsel Mesulam^{129,130}, Bruce L. Miller¹³⁷, Carol A. Miller¹³⁸, Joshua W. Miller¹⁰⁹, Thomas J. Montine¹³⁹, Edwin S. Monuki¹⁴⁰, John C. Morris^{51,141,142,106}, Shubhabrata Mukherjee⁵⁹, Amanda J. Myers⁶¹, Trung Nguyen¹⁰³, Sid O'Bryant¹⁴³, John M. Olichney¹⁴⁴, Marcia Ory¹⁴⁵, Raymond Palmer¹⁴⁶, Joseph E. Parisi¹⁴⁷, Henry L. Paulson^{18,20}, Valory Pavlik⁶⁴, David Paydarfar¹⁶, Victoria Perez⁶⁸, Elaine Peskind¹⁴⁸, Ronald C. Petersen⁴², Aimee Pierce⁶⁰, Marsha Polk¹⁴⁶, Wayne W. Poon⁶⁹, Huntington Potter¹⁴⁹, Liming Qu⁸, Mary Quiceno^{150,151}, Joseph F. Quinn^{116,117}, Ashok Raj⁵², Murray Raskind¹⁴⁸, Eric M.

Reiman^{101,152,153,154}, Barry Reisberg^{155,78}, Joan S. Reisch⁶⁵, John M. Ringman¹⁵⁶, Erik D. Roberson⁹⁴, Monica Rodriguear⁶⁴, Ekaterina Rogaeva¹⁵⁷, Howard J. Rosen⁴⁴, Roger N. Rosenberg¹⁰³, Donald R. Royall¹⁵⁸, Mark A. Sager²⁷, Mary Sano⁵⁰, Andrew J. Saykin^{73,159}, Julie A. Schneider^{29,31,160}, Lon S. Schneider^{161,57}, William W. Seeley⁴⁴, Susan H. Slifer², Scott Small^{4,5}, Amanda G. Smith⁵², Janet P. Smith⁶⁵, Joshua A. Sonnen¹¹⁸, Salvatore Spina⁸⁵, Peter St George-Hyslop^{162,163}, Robert A. Stern¹⁰, Alan B. Stevens^{164,165,166}, Stephen M. Strittmatter¹⁶⁷, David Sultzer¹⁶⁸, Russell H. Swerdlow⁴⁷, Rudolph E. Tanzi⁸⁸, Jeffrey L. Tilson¹⁶⁹, John Q. Trojanowski⁸, Juan C. Troncoso¹⁷⁰, Debby W. Tsuang^{38,148}, Vivianna M. Van Deerlin⁸, Linda J. van Eldik¹⁷¹, Jeffery M. Vance^{1,2}, Badri N. Vardarajan⁴, Robert Vassar^{129,130}, Harry V. Vinters^{172,156}, Jean-Paul Vonsattel⁴, Sandra Weintraub¹⁷³, Kathleen A. Welsh-Bohmer^{174,46}, Patrice L. Whitehead², Ellen M. Wijsman^{107,108,175}, Kirk C. Wilhelmsen⁵⁵, Benjamin Williams¹⁷⁶, Jennifer Williamson⁴, Henrik Wilms⁶⁸, Thomas S. Wingo¹²³, Thomas Wisniewski^{177,178}, Randall L. Woltjer¹⁷⁹, Martin Woon³⁷, Clinton B. Wright¹⁸⁰, Chuang-Kuo Wu⁶⁸, Steven G. Younkin^{21,71}, Chang-En Yu⁵⁹, Lei Yu^{29,31}, Xiongwei Zhu¹⁸¹, Brian W. Kunkle^{1,2}, William S. Bush^{3,9}, Li-San Wang⁸, Lindsay A. Farrer^{12,10,182,183,13}, Jonathan L. Haines^{3,9}, Richard Mayeux⁴, Margaret A. Pericak-Vance^{1,2}, Gerard D. Schellenberg⁸, Gyungah R. Jun^{7,13,182,8}, Christiane Reitz^{184,32,5,8}, Adam C. Naj^{6,8,8}

¹Dr. John T. Macdonald Foundation Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, Florida, USA, ²The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA, ³Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA, ⁴Taub Institute for Research in Alzheimer's Disease and the Aging Brain, The Gertrude H. Sergievsky Center, Department of Neurology, Columbia University, New York, New York, USA, ⁵Department of Neurology, Columbia University, New York, New York, USA, ⁶Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA, ⁷Department of Medicine (Biomedical Genetics), Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA, ⁸Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA, ⁹Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, Ohio, USA, ¹⁰Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA, ¹¹Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA, ¹²Department of Medicine (Biomedical Genetics), Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA, ¹³Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA, ¹⁴Sanders-Brown Center on Aging, Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, Kentucky, USA, ¹⁵Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA, ¹⁶Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, Texas, USA, ¹⁷Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA, ¹⁸Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA, ¹⁹Geriatric Research, Education and Clinical Center (GRECC), VA Ann Arbor Healthcare System (VAAHS), Ann Arbor, Michigan, USA, ²⁰Michigan Alzheimer's Disease Center, University of Michigan, Ann Arbor, Michigan, USA, ²¹Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA, ²²Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA, ²³Departments of Neurology,

Radiology, and Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA, ²⁴Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, Indiana, USA, ²⁵Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA, ²⁶Geriatric Research, Education and Clinical Center (GRECC), University of Wisconsin, Madison, Wisconsin, USA, ²⁷Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA, ²⁸Wisconsin Alzheimer's Disease Research Center, Madison, Wisconsin, USA, ²⁹Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA, ³⁰Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois, USA, ³¹Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA, ³²Gertrude H. Sergievsky Center, Columbia University, New York, New York, USA, ³³Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, Arizona, USA, ³⁴Departments of Psychiatry, Neurology, and Psychology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA, ³⁵National Alzheimer's Coordinating Center, University of Washington, Seattle, Washington, USA, ³⁶Department of Psychiatry and Hope Center Program on Protein Aggregation and Neurodegeneration, Washington University School of Medicine, St. Louis, Missouri, USA, ³⁷Department of Psychiatry, University of Texas at Austin/Dell Medical School, Austin, Texas, USA, ³⁸VA Puget Sound Health Care System/GRECC, Seattle, Washington, USA, ³⁹Department of Neurology, University of Washington, Seattle, Washington, USA, ⁴⁰Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA, ⁴¹Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA, ⁴²Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA, ⁴³Swedish Medical Center, Seattle, Washington, USA, ⁴⁴Department of Neurology, University of California San Francisco, San Francisco, California, USA, ⁴⁵Department of Neurosciences, University of California San Diego, La Jolla, California, USA, ⁴⁶Department of Medicine, Duke University, Durham, North Carolina, USA, ⁴⁷University of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, Kansas, USA, ⁴⁸Department of Genetics and Genomic Sciences, Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA, ⁴⁹Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA, ⁵⁰Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA, ⁵¹Department of Pathology and Immunology, Washington University, St. Louis, Missouri, USA, ⁵²USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa, Florida, USA, ⁵³Fred Hutchinson Cancer Research Center, Seattle, Washington, USA, ⁵⁴Mental Health and Behavioral Science Service, Bruce W. Carter VA Medical Center, Miami, Florida, USA, ⁵⁵Department of Genetics, University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA, ⁵⁶Neurogenetics Program, University of California Los Angeles, Los Angeles, California, USA, ⁵⁷Department of Neurology, University of Southern California, Los Angeles, California, USA, ⁵⁸Section of Gerontology and Geriatric Medicine Research, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA, ⁵⁹Department of Medicine, University of Washington, Seattle, Washington, USA, ⁶⁰Department of Neurology, University of California Irvine, Irvine, California, USA, ⁶¹Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA, ⁶²NeuroGenomics and Informatics, Washington University, St. Louis, Missouri, USA, ⁶³Department of Psychiatry, Washington University in St. Louis, St. Louis, Missouri, USA, ⁶⁴Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine, Houston, Texas, USA, ⁶⁵Department of Population and

Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA, ⁶⁶Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, New York, USA, ⁶⁷Department of Neurology, University of California Davis, Sacramento, California, USA, ⁶⁸Departments of Neurology, Pharmacology and Neuroscience, Texas Tech University Health Science Center, Lubbock, Texas, USA, ⁶⁹Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, California, USA, ⁷⁰Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, Florida, USA, ⁷¹Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA, ⁷²Rush Institute for Healthy Aging, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA, ⁷³Department of Medical and Molecular Genetics, Indiana University, Indianapolis, Indiana, USA, ⁷⁴Office of Strategy and Measurement, University of North Texas Health Science Center, Fort Worth, Texas, USA, ⁷⁵Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA, ⁷⁶Sanders-Brown Center on Aging, Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, Kentucky, USA, ⁷⁷Department of Neurology, Indiana University, Indianapolis, Indiana, USA, ⁷⁸Department of Psychiatry, New York University, New York, New York, USA, ⁷⁹C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Charlestown, Massachusetts, USA, ⁸⁰Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA, ⁸¹Department of Health Behavior and Health Systems, University of North Texas Health Science Center, Fort Worth, Texas, USA, ⁸²Department of Health Management and Policy, School of Public Health, University of North Texas Health Science Center, Fort Worth, Texas, USA, ⁸³Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, USA, ⁸⁴Emory Alzheimer's Disease Center, Emory University, Atlanta, Georgia, USA, ⁸⁵Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, Indiana, USA, ⁸⁶Department of Radiology, University of Washington, Seattle, Washington, USA, ⁸⁷Division of Genetics, Department of Medicine and Partners Center for Personalized Genetic Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA, ⁸⁸Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA, ⁸⁹Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA, ⁹⁰Division of Human Genetics, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA, ⁹¹Department of Pathology (Neuropathology), University of Pittsburgh, Pittsburgh, Pennsylvania, USA, ⁹²UCL Institute of Neurology, University College London, London, England, UK, ⁹³Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London, England, UK, ⁹⁴Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA, ⁹⁵Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, USA, ⁹⁶Department of Epidemiology and Population Health, Stanford University, Stanford, California, USA, ⁹⁷Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, USA, ⁹⁸Vanderbilt Memory and Alzheimer's Center, Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA, ⁹⁹Vanderbilt Genetics Institute, Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA, ¹⁰⁰Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA, ¹⁰¹Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona, USA, ¹⁰²Department of Pathology, Duke

University, Durham, North Carolina, USA, ¹⁰³Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, USA, ¹⁰⁴Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA, ¹⁰⁵Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA, ¹⁰⁶Hope Center Program on Protein Aggregation and Neurodegeneration, Washington University School of Medicine, St. Louis, Missouri, USA, ¹⁰⁷Department of Genome Sciences, University of Washington, Seattle, Washington, USA, ¹⁰⁸Department of Medicine (Medical Genetics), University of Washington, Seattle, Washington, USA, ¹⁰⁹Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, California, USA, ¹¹⁰Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA, ¹¹¹Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA, ¹¹²Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA, ¹¹³Department of Neurology, Albert Einstein College of Medicine, New York, New York, USA, ¹¹⁴Department of Neuroscience, Brigham Young University, Provo, Utah, USA, ¹¹⁵Department of Biology, Brigham Young University, Provo, Utah, USA, ¹¹⁶Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA, ¹¹⁷Department of Neurology, Portland Veterans Affairs Medical Center, Portland, Oregon, USA, ¹¹⁸Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA, ¹¹⁹Department of Pathology, Boston University, Boston, Massachusetts, USA, ¹²⁰Department of Neuropsychology, University of California San Francisco, San Francisco, California, USA, ¹²¹Department of Epidemiology, University of Washington, Seattle, Washington, USA, ¹²²Department of Neurobiology and Behavior, University of California Irvine, Irvine, California, USA, ¹²³Department of Neurology, Emory University, Atlanta, Georgia, USA, ¹²⁴Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA, ¹²⁵Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA, ¹²⁶National Center for PTSD at Boston VA Healthcare System, Boston, Massachusetts, USA, ¹²⁷Department of Psychiatry, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA, ¹²⁸Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA, ¹²⁹Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA, ¹³⁰Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA, ¹³¹Department of Medicine - Pulmonary, New York University, New York, New York, USA, ¹³²Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, USA, ¹³³Department of Pathology, University of California San Diego, La Jolla, California, USA, ¹³⁴School of Nursing Northwest Research Group on Aging, University of Washington, Seattle, Washington, USA, ¹³⁵Pfizer Worldwide Research and Development, New York, New York, USA, ¹³⁶Department of Pathology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA, ¹³⁷Weill Institute for Neurosciences, Memory and Aging Center, University of California San Francisco, San Francisco, California, USA, ¹³⁸Department of Pathology, University of Southern California, Los Angeles, California, USA, ¹³⁹Department of Pathology, Stanford University School of Medicine, Stanford, California, USA, ¹⁴⁰Department of Pathology and Laboratory Medicine and Alzheimer's Disease Research Center, University of California Irvine, Irvine, California, USA, ¹⁴¹Department of Neurology, Washington University, St. Louis, Missouri, USA, ¹⁴²Department of Psychiatry, Washington University School of Medicine, St. Louis Missouri, USA, ¹⁴³Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA, ¹⁴⁴Center for Mind and Brain and Department of Neurology, University of California

Davis, Sacramento, California, USA, ¹⁴⁵Center for Population Health and Aging, Texas A&M University Health Science Center, Lubbock Texas, USA, ¹⁴⁶Department of Family and Community Medicine, University of Texas Health Science Center San Antonio, San Antonio, Texas, USA, ¹⁴⁷Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA, ¹⁴⁸Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA, ¹⁴⁹Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA, ¹⁵⁰Department of Internal Medicine and Geriatrics, University of North Texas Health Science Center, Fort Worth, Texas, USA, ¹⁵¹Department of Medical Education, TCU/UNTHSC School of Medicine, Fort Worth, Texas, ¹⁵²Arizona Alzheimer's Consortium, Phoenix, Arizona, USA, ¹⁵³Banner Alzheimer's Institute, Phoenix, Arizona, USA, ¹⁵⁴Department of Psychiatry, University of Arizona, Phoenix, Arizona, USA, ¹⁵⁵Alzheimer's Disease Center, New York University, New York, New York, USA, ¹⁵⁶Department of Neurology, University of California Los Angeles, Los Angeles, California, USA, ¹⁵⁷Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada, ¹⁵⁸Departments of Psychiatry, Medicine, Family and Community Medicine, and the Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UT Health Science Center at San Antonio, San Antonio, Texas, USA, ¹⁵⁹Department of Radiology and Imaging Sciences, Indiana University, Indianapolis, Indiana, USA, ¹⁶⁰Department of Pathology (Neuropathology), Rush University Medical Center, Chicago, Illinois, USA, ¹⁶¹Department of Psychiatry, University of Southern California, Los Angeles, California, USA, ¹⁶²Cambridge Institute for Medical Research, University of Cambridge, Cambridge, England, UK, ¹⁶³Faculty of Medicine, Department of Medicine (Neurology), University of Toronto, Toronto, Ontario, Canada, ¹⁶⁴Center for Applied Health Research, Baylor Scott & White Health, Temple, Texas, ¹⁶⁵Center for Population Health and Aging, Texas A&M University Health Science Center, Lubbock Texas, USA, ¹⁶⁶College of Medicine, Texas A&M University Health Science Center, College Station, Texas, USA, ¹⁶⁷Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, New Haven, Connecticut, USA, ¹⁶⁸Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, California, USA, ¹⁶⁹Renaissance Computing Institute, University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA, ¹⁷⁰Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA, ¹⁷¹Sanders-Brown Center on Aging, Department of Neuroscience, College of Medicine, University of Kentucky, Lexington, Kentucky, USA, ¹⁷²Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA, ¹⁷³Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA, ¹⁷⁴Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina, USA, ¹⁷⁵Department of Biostatistics, University of Washington, Seattle, Washington, USA, ¹⁷⁶Department of Neurology, Section of Gerontology and Geriatric Medicine Research, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA, ¹⁷⁷Department of Psychiatry, New York University Grossman School of Medicine, New York, New York, USA, ¹⁷⁸Center for Cognitive Neurology and Departments of Neurology and Pathology, New York University Grossman School of Medicine, New York, USA, ¹⁷⁹Department of Pathology, Oregon Health and Science University, Portland, Oregon, USA, ¹⁸⁰Evelyn F. McKnight Brain Institute, Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, USA, ¹⁸¹Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA, ¹⁸²Department of Ophthalmology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA,

¹⁸³Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA, ¹⁸⁴Department of Epidemiology, Columbia University, New York, New York, USA

* These first authors have made equal contributions to this manuscript.

§ These senior authors have made equal contributions to this manuscript.

Author Contributions

Study Design and Conception: F.R., P.B., G.T., K.L.L., L.-S.W., R.M., L.A.F., J.L.H., M.A.P.-V., G.D.S., G.R.J., C.R., and A.C.N. *Sample Contribution:* E.A., P.M.A., A.A., M.S.A., R.L.A., M.A., L.A., L.G.A., S.E.A., S.Asthana, C.S.A., G.A., C.T.B., R.C.B., L.L.B., T.G.B., J.T.B., G.W.B., D.Beekly, B.B., D.Bennett, J.B., M.E.F., T.D.B., D.Blackler, B.F.B., J.D.B., A.Boxer, J.B.B., J.R.B., J.M.B., J.D.Buxbaum, N.J.C., L.B.C., C.Cao, C.S.C., C.M.C., R.M.C., M.M.C., S.C., M.-F.C., N.A.C., H.C.C., J.C., S.Craft, P.K.C., D.H.C., E.A.C., C.Cruchaga, M.L.C., M.C., E.D., B.D., P.L.D., C.D., J.C.D., M.Dick, D.W.D., B.A.D., R.S.Doody, R.D., N.E.-T., D.A.E., K.M.F., T.J.F., K.B.F., D.W.F., M.R.F., V.F.-H., S.F., T.M.F., M.P.F., D.R.G., A.G., M.Gearing, D.H.G., B.G., J.R.G., A.M.G., T.G., N.R.G.-R., R.C.G., J.H.G., H.H., J.H., R.L.H., O.Harari, J.Hardy, L.E.H, E.H., V.H., M.H., L.S.H., R.M.H., M.J.H., C.M.H., B.T.H., L.S.Hynan, L.I., G.P.J., S.J., L.W.J., K.J., L.J., M.I.K., A.Karydas, M.J.K., J.S.K., J.A.K., C.D.K., A.Khaleeq, R.K., J.K., N.W.K., J.H.K., W.K., F.M.L., J.J.L., E.B.L., A.L., J.B.L., A.I.L., A.P.L., R.B.L., M.Logue, O.L.L., C.G.L., D.M., D.C.M., E.R.M., F.M., D.C.Mash, E.M., P.M., A.M., W.C.M., S.M.M., A.N.M., S.M., A.C.M., M.Mesulam, J.Mez, B.L.M., C.A.M., J.W.M., T.J.M., E.S.Monuki, J.C.M., S.Mukherjee, A.J.M., T.N., S.O., J.M.O., M.O., R.P., J.E.P., H.L.P., V.P., D.P., V.Perez, E.P., R.C.P., A.P., M.P., W.W.P., H.P., L.Q., M.Q., J.F.Q., A.R., M.R., E.M.R., B.R., J.S.R., J.M.R., E.D.R., M.Rodriguear, E.R., H.J.R., R.N.R., D.R.R., M.A.S., M.S., A.J.S., J.A.S., L.S.S., W.W.S., S.H.S., S.Small, A.G.S., J.P.S., Y.E.Song, J.A.Sonnen, S.Spina, P.S.G.-H., R.A.S., A.B.Stevens, S.M.S., D.Sultzzer, R.H.S., R.E.T., J.T., G.T., J.Q.T., J.C.T., D.W.T., V.M.VD., L.J.VE., J.M.V., R.Vassar, H.V.V., J.-P.V., S.W., K.A.W.-B., P.L.W., E.M.W., K.C.W., B.W., J.Williamson, H.W., T.S.W., T.W., R.L.W., M.Woon, C.B.W., C.-K.W., S.G.Y., C.-E.Y., L.Y., X.Z., X.Zhou, and C.Z.; *Data Generation:* A.C.N., J.S., Y.Z., D.L.D., J.J.F., K.H.-N., J.Haut, A.B.K., O.V., J.M., L.S.Hynan, C.D.K., J.P.S., A.C.; *Analysis:* F.R., P.B., G.T., N.K., J.S., C.Z., W.-P.L., J.Haut, K.H.-N., N.R.W., Y.Z., J.J.F., M.A.G., Y.Y.L., P.P.K., D.L., E.L.daF., J.B.M., E.L.P., J.P., R.M.S., Y.E.S., X.Z., T.I., O.P., O.V., A.B.K., G.R.J., C.R., and A.C.N. *Manuscript Preparation:* F.R., P.B., G.T., N.K., J.S., C.Z., L.-S.W., R.M., L.A.F., J.L.H., M.A.P.-V., G.D.S., G.R.J., C.R., and A.C.N.; *Study Supervision/ Management:* F.R., P.B., G.T., L.-S.W., L.A.F., J.L.H., R.M., M.A.P.-V., G.D.S., G.R.J., C.R., and A.C.N.

Competing Interests statement

D.Blacker is a consultant for Biogen, Inc. R.C.P. is a consultant for Roche, Inc., Merck, Inc., Genentech, Inc., Biogen, Inc., and Eli Lilly. A.M.G. is a member of the scientific advisory board for Denali Therapeutics. N.E.-T. is a consultant for Cytos. J. Hardy holds a collaborative grant with Cytos cofunded by the Department of Business (Biz). J.C.M. is currently participating in clinical trials of antimentia drugs from Eli Lilly and Company, Biogen, and Janssen. J.C.M. serves as a consultant for Lilly USA. J.C.M. also receives research support from Eli Lilly/Avid Radiopharmaceuticals and is funded by NIH grants P50 AG005681, P01 AG003991, P01 AG026276, and UF1 AG032438. B.T.H. has a family member who works at Novartis and owns stock in Novartis. B.T.H. serves on the SAB of Dewpoint and owns stock. B.T.H. also serves on a scientific advisory board or is a consultant for Avrobio, AZtherapies, Biogen, Cell Signaling, PPF, Novartis, the US Dept of Justice, Takeda, Vigil, W20 group, and Seer. B.T.H.'s laboratory is supported by Sponsored research agreements with Abbvie, F Prime, and research grants from the National Institutes of Health, Cure Alzheimer's Fund, Tau Consortium, and the JPB Foundation.